107 related articles for article (PubMed ID: 3121370)
1. Antagonist effect of RU 486 on transcription of glucocorticoid-regulated genes.
Busso N; Collart M; Vassalli JD; Belin D
Exp Cell Res; 1987 Dec; 173(2):425-30. PubMed ID: 3121370
[TBL] [Abstract][Full Text] [Related]
2. Glucocorticoid-modulated gene expression of tissue- and urinary-type plasminogen activator and plasminogen activator inhibitor 1 and 2.
Medcalf RL; Van den Berg E; Schleuning WD
J Cell Biol; 1988 Mar; 106(3):971-8. PubMed ID: 3126194
[TBL] [Abstract][Full Text] [Related]
3. Glucocorticoid modulation of plasminogen activators and of one of their inhibitors in the human mammary carcinoma cell line MDA-MB-231.
Busso N; Belin D; Failly-Crépin C; Vassalli JD
Cancer Res; 1987 Jan; 47(2):364-70. PubMed ID: 3098408
[TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor-alpha regulates mRNA for urokinase-type plasminogen activator and type-1 plasminogen activator inhibitor in human neoplastic cell lines.
Georg B; Helseth E; Lund LR; Skandsen T; Riccio A; Danø K; Unsgaard G; Andreasen PA
Mol Cell Endocrinol; 1989 Jan; 61(1):87-96. PubMed ID: 2501120
[TBL] [Abstract][Full Text] [Related]
5. Biological mechanisms underlying the clinical effects of RU 486: modulation of cultured endometrial stromal cell plasminogen activator and plasminogen activator inhibitor expression.
Lockwood CJ; Krikun G; Papp C; Aigner S; Schatz F
J Clin Endocrinol Metab; 1995 Apr; 80(4):1100-5. PubMed ID: 7714076
[TBL] [Abstract][Full Text] [Related]
6. Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines.
Quax PH; van Leeuwen RT; Verspaget HW; Verheijen JH
Cancer Res; 1990 Mar; 50(5):1488-94. PubMed ID: 2105839
[TBL] [Abstract][Full Text] [Related]
7. Modulation of urokinase-type plasminogen activator messenger RNA levels in human synovial fibroblasts by interleukin-1, retinoic acid, and a glucocorticoid.
Vitti G; Hamilton JA
Arthritis Rheum; 1988 Aug; 31(8):1046-51. PubMed ID: 3136776
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activators in the mouse mammary gland. Decreased expression during lactation.
Busso N; Huarte J; Vassalli JD; Sappino AP; Belin D
J Biol Chem; 1989 May; 264(13):7455-7. PubMed ID: 2496128
[TBL] [Abstract][Full Text] [Related]
9. Modulations of functional activity in differentiated macrophages are accompanied by early and transient increase or decrease in c-fos gene transcription.
Collart MA; Belin D; Vassalli JD; Vassalli P
J Immunol; 1987 Aug; 139(3):949-55. PubMed ID: 3110291
[TBL] [Abstract][Full Text] [Related]
10. Induction of urokinase-type plasminogen activator receptor by IL-1 beta.
Hasegawa T; Sorensen L; Dohi M; Rao NV; Hoidal JR; Marshall BC
Am J Respir Cell Mol Biol; 1997 Jun; 16(6):683-92. PubMed ID: 9191470
[TBL] [Abstract][Full Text] [Related]
11. Reciprocal regulation of tissue-type and urokinase-type plasminogen activators in the differentiation of murine preadipocyte line 3T3-L1 and the hormonal regulation of fibrinolytic factors in the mature adipocytes.
Seki T; Miyasu T; Noguchi T; Hamasaki A; Sasaki R; Ozawa Y; Okukita K; Declerck PJ; Ariga T
J Cell Physiol; 2001 Oct; 189(1):72-8. PubMed ID: 11573206
[TBL] [Abstract][Full Text] [Related]
12. Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53.
Kunz C; Pebler S; Otte J; von der Ahe D
Nucleic Acids Res; 1995 Sep; 23(18):3710-7. PubMed ID: 7479001
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor and pro-inflammatory cytokines regulate the expression of components of plasminogen activation system in U373-MG astrocytoma cells.
Kasza A; Kowanetz M; Poślednik K; Witek B; Kordula T; Koj A
Cytokine; 2001 Dec; 16(5):187-90. PubMed ID: 11814314
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activators and their inhibitors in a human mammary cell line (HBL-100). Modulation by glucocorticoids.
Busso N; Belin D; Failly-Crépin C; Vassalli JD
J Biol Chem; 1986 Jul; 261(20):9309-15. PubMed ID: 3087993
[TBL] [Abstract][Full Text] [Related]
15. Synergistic induction of apoptosis with glucocorticoids and 3',5'-cyclic adenosine monophosphate reveals agonist activity by RU 486.
Gruol DJ; Altschmied J
Mol Endocrinol; 1993 Jan; 7(1):104-13. PubMed ID: 8383286
[TBL] [Abstract][Full Text] [Related]
16. The expression and localization of urokinase-type plasminogen activator and its type 1 inhibitor are regulated by retinoic acid and fibroblast growth factor in human teratocarcinoma cells.
Tienari J; Alanko T; Lehtonen E; Saksela O
Cell Regul; 1991 Apr; 2(4):285-97. PubMed ID: 1905574
[TBL] [Abstract][Full Text] [Related]
17. Advanced glycation end products stimulate plasminogen activator activity via GM-CSF in RAW 264.7 cells.
Saishoji T; Higashi T; Ikeda K; Sano H; Jinnouchi Y; Ogawa M; Horiuchi S
Biochem Biophys Res Commun; 1995 Dec; 217(1):278-85. PubMed ID: 8526923
[TBL] [Abstract][Full Text] [Related]
18. A labile repressor acts through the NFkB-like binding sites of the human urokinase gene.
Novak U; Cocks BG; Hamilton JA
Nucleic Acids Res; 1991 Jun; 19(12):3389-93. PubMed ID: 1905804
[TBL] [Abstract][Full Text] [Related]
19. In vitro effects of interleukin 1 on the synthesis of metalloproteases, TIMP, plasminogen activators and inhibitors in human articular cartilage.
Martel-Pelletier J; Zafarullah M; Kodama S; Pelletier JP
J Rheumatol Suppl; 1991 Feb; 27():80-4. PubMed ID: 1851231
[TBL] [Abstract][Full Text] [Related]
20. Suppression of urokinase-type plasminogen activator mRNA levels in human fibrosarcoma cells and synovial fibroblasts by anti-inflammatory glucocorticoids.
Medcalf RL; Richards RI; Crawford RJ; Hamilton JA
EMBO J; 1986 Sep; 5(9):2217-22. PubMed ID: 3780677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
